157 related articles for article (PubMed ID: 35263200)
21. Integrated bioinformatics analysis reveals dynamic candidate genes and signaling pathways involved in the progression and prognosis of diffuse large B-cell lymphoma.
Charwudzi A; Meng Y; Hu L; Ding C; Pu L; Li Q; Xu M; Zhai Z; Xiong S
PeerJ; 2021; 9():e12394. PubMed ID: 34760386
[TBL] [Abstract][Full Text] [Related]
22. NFYB potentiates STK33 activation to promote cisplatin resistance in diffuse large B-cell lymphoma.
Feng L; Xu X; Zhao K
Leuk Res; 2021 Dec; 111():106708. PubMed ID: 34536775
[TBL] [Abstract][Full Text] [Related]
23. Deregulated expression of miR-224 and its target gene: CD59 predicts outcome of diffuse large B-cell lymphoma patients treated with R-CHOP.
Song G; Song G; Ni H; Gu L; Liu H; Chen B; He B; Pan Y; Wang S; Cho WC
Curr Cancer Drug Targets; 2014; 14(7):659-70. PubMed ID: 25146331
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of a five-gene signature associated with stromal infiltration for diffuse large B-cell lymphoma.
Nan YY; Zhang WJ; Huang DH; Li QY; Shi Y; Yang T; Liang XP; Xiao CY; Guo BL; Xiang Y
World J Clin Cases; 2021 Jun; 9(18):4585-4598. PubMed ID: 34222425
[TBL] [Abstract][Full Text] [Related]
25. Identification of hub genes associated with the pathogenesis of diffuse large B-cell lymphoma subtype one characterized by host response via integrated bioinformatic analyses.
Zhou L; Ding L; Gong Y; Zhao J; Xin G; Zhou R; Zhang W
PeerJ; 2020; 8():e10269. PubMed ID: 33240622
[TBL] [Abstract][Full Text] [Related]
26. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.
Petrich AM; Leshchenko V; Kuo PY; Xia B; Thirukonda VK; Ulahannan N; Gordon S; Fazzari MJ; Ye BH; Sparano JA; Parekh S
Clin Cancer Res; 2012 May; 18(9):2534-44. PubMed ID: 22338016
[TBL] [Abstract][Full Text] [Related]
27. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index.
Due H; Brøndum RF; Young KH; Bøgsted M; Dybkær K
BMC Cancer; 2020 Mar; 20(1):237. PubMed ID: 32192453
[TBL] [Abstract][Full Text] [Related]
28. LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy.
Peng W; Wu J; Feng J
Clin Exp Med; 2017 Feb; 17(1):1-8. PubMed ID: 26475621
[TBL] [Abstract][Full Text] [Related]
29. Identification of gene modules associated with survival of diffuse large B-cell lymphoma treated with CHOP-based chemotherapy.
Gao Y; Sun B; Hu J; Ren H; Zhou H; Chen L; Liu R; Zhang W
Pharmacogenomics J; 2020 Oct; 20(5):705-716. PubMed ID: 32042095
[TBL] [Abstract][Full Text] [Related]
30. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
[TBL] [Abstract][Full Text] [Related]
31. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma.
Singh RR; Kunkalla K; Qu C; Schlette E; Neelapu SS; Samaniego F; Vega F
Oncogene; 2011 Dec; 30(49):4874-86. PubMed ID: 21625222
[TBL] [Abstract][Full Text] [Related]
32. TCFL5 knockdown sensitizes DLBCL to doxorubicin treatment via regulation of GPX4.
Lu X; Zhang Q; Xie Y
Cell Signal; 2023 Oct; 110():110831. PubMed ID: 37516394
[TBL] [Abstract][Full Text] [Related]
33. Identification of potential key genes associated with diffuse large B-cell lymphoma based on microarray gene expression profiling.
Luo X; Shi F; Qiu H; Tong Y; Gao X
Neoplasma; 2017; 64(6):824-833. PubMed ID: 28895406
[TBL] [Abstract][Full Text] [Related]
34. Transcriptome sequencing reveals thousands of novel long non-coding RNAs in B cell lymphoma.
Verma A; Jiang Y; Du W; Fairchild L; Melnick A; Elemento O
Genome Med; 2015 Nov; 7():110. PubMed ID: 26521025
[TBL] [Abstract][Full Text] [Related]
35. Pathway activation in large B-cell non-Hodgkin lymphoma cell lines by doxorubicin reveals prognostic markers of in vivo response.
Houldsworth J; Petlakh M; Olshen AB; Chaganti RS
Leuk Lymphoma; 2008 Nov; 49(11):2170-80. PubMed ID: 19021061
[TBL] [Abstract][Full Text] [Related]
36. Bioinformatic validation identifies candidate key genes in diffuse large-B cell lymphoma.
Huang Q; Liu F; Shen J
Per Med; 2019 Jul; 16(4):313-323. PubMed ID: 31331250
[No Abstract] [Full Text] [Related]
37. IQGAP2 acts as an independent prognostic factor and is related to immunosuppression in DLBCL.
Tang T; Wang J; Zhang L; Cheng Y; Saleh L; Gu Y; Zhang H
BMC Cancer; 2021 May; 21(1):603. PubMed ID: 34034707
[TBL] [Abstract][Full Text] [Related]
38. Long noncoding RNA lncARSR confers resistance to Adriamycin and promotes osteosarcoma progression.
Shen P; Cheng Y
Cell Death Dis; 2020 May; 11(5):362. PubMed ID: 32404870
[TBL] [Abstract][Full Text] [Related]
39. Agent Repurposing for the Treatment of Advanced Stage Diffuse Large B-Cell Lymphoma Based on Gene Expression and Network Perturbation Analysis.
Xiang C; Ni H; Wang Z; Ji B; Wang B; Shi X; Wu W; Liu N; Gu Y; Ma D; Liu H
Front Genet; 2021; 12():756784. PubMed ID: 34721544
[TBL] [Abstract][Full Text] [Related]
40. Downregulation of USP18 reduces tumor-infiltrating activated dendritic cells in extranodal diffuse large B cell lymphoma patients.
Zhao C; Huang R; Zeng Z; Yang S; Lu W; Liu J; Wei Y; Guo H; Zhang Y; Yan P; Huang Z; Shi J
Aging (Albany NY); 2021 May; 13(10):14131-14158. PubMed ID: 34001679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
